Navigation Links
Cordex Pharma Forms Heart Failure Medical Advisory Board
Date:2/11/2009

molecules play critical roles in cellular metabolism and signal transduction, the manipulation of which constitute novel therapeutic modalities for the treatment of major cardiovascular disorders. Cordex has a portfolio of investigational medicines, two of which are in late stages of clinical development. Cordex's ATPace is expected to enter a Phase 3 clinical trial for the treatment of paroxysmal supraventricular tachycardia in 2009. Cordex's CDP-1050 is also expected to commence a Phase 2 clinical trial for the treatment of heart failure in 2009. In addition, Cordex has a preclinical program to develop new chemical entities that target a recently discovered pathway in the pathophysiology of chronic obstructive pulmonary disease. For further information regarding Cordex, please visit the company's website at www.cordexpharma.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements. The forward-looking statements are based on current expectations, estimates and projections made by management. Cordex intends for the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," or variations of such words are intended to identify such forward-looking statements. All statements in this release regarding the future outlook related to Cordex are forward-looking statements, including, but not limited to, the statements regarding CDP-1050 as a paradigm for the treatment of heart failure, satisfaction of the medical community and regulatory authorities as to the
'/>"/>

SOURCE Cordex Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cordex Pharma Presents New Frontiers in Cardiovascular Medicines on January 29
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... 2015 The Thomas Brain Health ... a groundbreaking pilot study to see if early ... as little as three to six months. , ... nutritional medicine—will aggressively target and simultaneously treat the ... aging brain. These include oxidative stress, neuroinflammation, mitochondrial ...
(Date:4/23/2015)... April 23, 2015 BioTE Medical President and ... "Age Healthier Live Happier - Avoiding Over-Medication through Natural ... Management Medicine Group Conference at JW Marriott / Ritz ... ",Age Healthier Live Happier, is a welcomed response ... and searching for a higher quality of life thanks ...
(Date:4/23/2015)... SAN DIEGO , April 23, 2015  Neurocrine ... the Company will report its first quarter 2015 results ... 2015. Neurocrine will then host a live conference call and ... Company update Thursday morning, April 30, 2015 at 8:00 ... Participants can access the live conference call by dialing ...
(Date:4/23/2015)... Jose, California (PRWEB) April 23, 2015 ... Predictive diagnostics refer to a series of genetic ... as cystic fibrosis, Lou Gehrig's disease, Huntington's disease, ... in examining the gene composition and interaction in ... the disease as well as the response to ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... Firmenich,s world leadership in the ... flavor ingredients, - New S2383 flavor enhancer may be used in ... healthcare products to reduce the need for sucralose, ... Inc. (Nasdaq: SNMX ), a leading company,focused on using proprietary ...
... BOSTON, Nov. 6 Solos Endoscopy, Inc. (Pink,Sheets: SNDY) ... a,significant purchase order for laparoscopic instruments from the St. ... client of Solos,Endoscopy,s for over 19 yrs and it ... Saint Mary,s Hospital has played a vital role in ...
... Inc. (NTI(R)) (Nasdaq: NTII ) today announced its ... first quarter of the,company,s fiscal year ending June 30, ... was $3.6 million, compared to $3.9 million for the,three ... million,for the first quarter of fiscal 2009 compared to ...
Cached Biology Technology:SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 2SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 3SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 4SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE 5Solos Endoscopy, Inc. Receives Purchase Order from Connecticut Hospital 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 2Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 3Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 4Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results 5
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/14/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces that its Wocket® smart ... Design Awards under the category  ,Product Design – Technology,. ... are part of a global multi-disciplinary awards program. The ... marketplace, industry and judging panel. Winners will be announced ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) has ... - NEC" report to their offering. ... to supply a range of IT security management and ... on the development of a Big Data and cloud ... Asia-Pacific region is a core ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3NEC Security Competitive Profile 2015 2
... After a year of studying up close the symbiotic relationship ... University biologist has advanced the scientific understanding of biological diversity. ... relationship between two or more organisms that can be parasitic ... diversity as predation and competition. The Proceedings ...
... , Feb. 5, 2013 Reportlinker.com ... is available in its catalogue: ... and Prognostic Biomarkers, 2013 ... Endothelial Growth Factor (VEGF), which plays an ...
... When it comes to gene sequencing and personalized medicine for ... proteins are relatively easy to target with drugs and plenty ... study, University of Michigan Comprehensive Cancer Center researchers assess the ... kinases are acting up in a particular tumor. They go ...
Cached Biology News:Pirate-like flies connect symbiosis to diversity 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 2VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 3VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 4VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2013 5Study finds potential to match tumors with known cancer drugs 2Study finds potential to match tumors with known cancer drugs 3
... purified Formulation: 0.15M NaCl, 20mM MOPS, ... 1mM MgCl2, 1mM EGTA, 10 Properites: ... proteins Purification: DEAE chromatography, divalent cation ... filtration chromatography Quality Assurance: routinely evaluated ...
... Endogenous potent vasoconstrictor peptide. Displays ... modulates vascular tonus. ET-1, ET-2, and ET-3 ... genes. ET-2 and ET-3 are similar to ... amino acids, respectively. All three isopeptides produce ...
Human sVCAM-1/CD106 ELI-PAIR Kit...
HNF-1 Purified Anti-Mouse, Anti-Rat, Anti-Rabbit, Anti-Human clone 2, Isotype Mouse IgG 1 , 50 µg Consult technical datasheet for details....
Biology Products: